Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Company Limited American Depositary Shares (each
(NY:
TAK
)
17.78
+0.02 (+0.09%)
Streaming Delayed Price
Updated: 11:41 AM EST, Mar 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
October 26, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone.
↗
October 23, 2023
Analysts say Alkermes' drug is clearly active. But investors have concerns.
Via
Investor's Business Daily
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
↗
October 21, 2023
KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin...
Via
Talk Markets
A Look Into Takeda Pharmaceutical Inc's Price Over Earnings
↗
October 19, 2023
Via
Benzinga
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
October 18, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Looking Into Takeda Pharmaceutical's Recent Short Interest
↗
October 11, 2023
Via
Benzinga
Takeda's Crohn's Disease Fistulas Candidates Fall Short In Mid-Stage Study, Settles Tax Dispute With Irish Revenue Commissioners
↗
October 18, 2023
Takeda Pharmaceutical Co Ltd (NYSE: TAK) released topline data from the Phase 3 ADMIRE-CD II study, assessing Alofisel (darvadstrocel) for complex Crohn's Perianal Fistulas (CPF).
Via
Benzinga
Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
October 17, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
October 17, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
A Look Into Takeda Pharmaceutical Inc's Price Over Earnings
↗
October 04, 2023
Via
Benzinga
Looking Into Takeda Pharmaceutical's Recent Short Interest
↗
September 25, 2023
Via
Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
↗
September 08, 2023
Via
Benzinga
Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years
October 03, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
↗
October 03, 2023
Benzinga
Via
Benzinga
Takeda Withdraws Lung Cancer Drug From US After Failed Confirmatory Trial
↗
October 03, 2023
Following discussions with the FDA, Takeda Pharmaceutical Co Ltd (NYSE: TAK) will voluntarily withdraw Exkivity (mobocertinib)
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
October 02, 2023
Via
Benzinga
Takeda Provides Update on EXKIVITY® (mobocertinib)
October 02, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Can Japan's Economy Continue To Blossom If Bank of Japan Raises Rates? Apparently So.
↗
October 02, 2023
Amid an economic climate of high interest rates in the US and a slumber among China stocks led by a downturn in the property market, Japan’s economy lies in stark contrast to the antipathy that...
Via
Benzinga
Topics
Economy
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
September 29, 2023
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —
From
HUTCHMED (China) Limited
Via
GlobeNewswire
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
September 27, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Morphic Therapeutic's Stock Plunges On Monday - Here's Why?
↗
September 25, 2023
Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results...
Via
Benzinga
The Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two Days
↗
September 25, 2023
The company is working on a treatment for ulcerative colitis. But competitive questions linger.
Via
Investor's Business Daily
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
September 25, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Top 4 Health Care Stocks That Should Keep You Up At Night
↗
September 21, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
September 20, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Is This 250-Year-Old Japanese Big Pharma Giant Selling For Half Price Right Now?
↗
September 18, 2023
When it comes to Big Pharma, Japan’s Takeda Pharmaceutical Co Ltd (NYSE: TAK) is a conservative play that could prove to be a big winner given its cheap valuation and suite of new drugs that portend to...
Via
Benzinga
Ovarian Cancer Player ImmunoGen Can Potentially Be Attractive M&A Target: JP Morgan
↗
September 13, 2023
JP Morgan upgraded ImmunoGen Inc (NASDAQ: IMGN) from Neutral to Overweight with a price target of $22, up from $9, based on insights gathered from a recent physician survey, which focused on the...
Via
Benzinga
Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries
September 13, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
September 13, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
September 11, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
